Scientists arm immune cells to fight Virus-Linked cancer
NCT ID NCT04139057
Summary
This trial tested a new immunotherapy approach for Epstein-Barr virus (EBV)-positive head and neck cancers that have returned or spread. Researchers collected patients' own immune cells, engineered them to recognize EBV proteins on cancer cells, and added a component to block cancer's immune-suppressing signals. The study aimed to find the safest and most effective dose of these modified cells for 10 patients with advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.